[Hanyu Pharmaceutical: Preclinical studies of HY3003 tablets show that the weight loss effect is better than semaglutide] On October 26, Hanyu Pharmaceutical (300199.SZ) announced that the company completed a preclinical pharmacodynamics comparative study of HY3003 tablets for weight loss indications. The results showed that in the obesity model of DIO mice and DIO rats, the weight loss effect of HY3003 tablets was better than that of the marketed drug semaglutide tablets under the same experimental conditions. HY3003 tablets are the company's GLP-1R/GIPR/GCGR triple receptor agonist oral preparations. It is intended to be used for indications such as weight loss, type 2 diabetes, and metabolic-related steatohepatitis. It is the company's blockbuster innovative drug in the field of metabolic diseases.